Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral: Vanier Canada Graduate Scholarships

University of Calgary

$150,000.00

The Role of Nuclear Receptors in Tissue Fibrosis - Identifying New Targets to Treat Fibrostenotic Crohn's Disease

FY 2015-16

Summary
Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBD) that are characterized by chronic inflammation in specific regions of the gastrointestinal tract, leading to extensive tissue damage and alterations in overall gut function. While some patients with IBD can be managed by existing therapies, a significant number of patients with CD and UC are not responsive to drugs. They manifest severe disease complications often requiring surgical intervention. In patients with CD, severe and uncontrolled chronic intestinal inflammation can lead to structural changes in the gut wall and extreme narrowing of the intestine, a clinical term called stricturing. This type of CD, clinically referred to as fibrostenotic (fibro - referring to the structural changes; stenotic - referring to the narrowing of the intestine) disease, requires surgery to remove the damaged tissue. In North America, intestinal stricture formation will occur in 30-50% of CD patients within 10 years of disease onset. Unfortunately, more than 50% of those who undergo surgery to remove the damaged tissue will experience stricture recurrence. Despite significant advances in the treatment of CD, current therapies do nothing to target the biological pathways that contribute to stricture formation. It is currently thought that intestinal narrowing/stricture formation is driven by an abnormal response to inflammatory injury and alterations in the function of specific cell types within the intestinal wall. In the current application I intend to assess the role that specific receptor play in regulating the processes that contribute to the pathogenic tissue remodeling observed in patients with CD. The study is a new area of IBD research whose findings could dramatically change the lives of fibrostenotic CD patients in Canada. Should this studies succeed, it will be the first description of a therapy to target the cells stricture formation. There won't be need for surgical interventions.
Program
Doctoral: Vanier Canada Graduate Scholarships
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
339749
Name
Ikeh Chibueze
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
The Role of Nuclear Receptors in Tissue Fibrosis - Identifying New Targets to Treat Fibrostenotic Crohn's Disease
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Crohn'S Disease; Inflammatory Bowel Disease; Nr1i2/Pxr; Nr4a1/Nur77; Nuclear Receptors; Ulcerative Colities
Abstract
Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBD) that are characterized by chronic inflammation in specific regions of the gastrointestinal tract, leading to extensive tissue damage and alterations in overall gut function. While some patients with IBD can be managed by existing therapies, a significant number of patients with CD and UC are not responsive to drugs. They manifest severe disease complications often requiring surgical intervention. In patients with CD, severe and uncontrolled chronic intestinal inflammation can lead to structural changes in the gut wall and extreme narrowing of the intestine, a clinical term called stricturing. This type of CD, clinically referred to as fibrostenotic (fibro - referring to the structural changes; stenotic - referring to the narrowing of the intestine) disease, requires surgery to remove the damaged tissue. In North America, intestinal stricture formation will occur in 30-50% of CD patients within 10 years of disease onset. Unfortunately, more than 50% of those who undergo surgery to remove the damaged tissue will experience stricture recurrence. Despite significant advances in the treatment of CD, current therapies do nothing to target the biological pathways that contribute to stricture formation. It is currently thought that intestinal narrowing/stricture formation is driven by an abnormal response to inflammatory injury and alterations in the function of specific cell types within the intestinal wall. In the current application I intend to assess the role that specific receptor play in regulating the processes that contribute to the pathogenic tissue remodeling observed in patients with CD. The study is a new area of IBD research whose findings could dramatically change the lives of fibrostenotic CD patients in Canada. Should this studies succeed, it will be the first description of a therapy to target the cells stricture formation. There won't be need for surgical interventions.
Competitiondate
201511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Ikeh, Chibueze
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~
University of Calgary - $150,000 Grant (2015-16) | Canada Spends